Restalyst Pte Ltd of Singapore at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine
Manufacturers

Restalyst Pte Ltd

50 Loyang Way, 508743 Singapore
Singapore
Telephone +65 65433640
Fax +65 65433645
restalyst.info@reste-group.com

This company is co-exhibitor of
Singapore Manufacturing Federation

Hall map

MEDICA 2018 hall map (Hall 3): stand G74

Fairground map

MEDICA 2018 fairground map: Hall 3

Contact

Ivan Lim

Business Manager

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

Our products

Product category: Diagnostic tests for cancer

Restalyst REAAD™ Series

Restalyst NPC-REAAD™ Anti-EBV EA IgA ELISA is a CE-IVD certified in-vitro diagnostic medical device, for the early detection and diagnostic application for nasopharyngeal carcinoma or, commonly known as, head-neck-throat cancers.

Restalyst GC-REAAD™ ITIH3 ELISA is a CE-IVD certified in-vitro diagnostic medical device, for the early detection and diagnostics application for gastric carcinoma or, commonly known as, stomach cancer.  

Restalyst HCC-REAAD™ ERBB3 ELISA incorporating ERBB3 and AFP, is a CE-IVD certified in-vitro diagnostic medical device, for the early detection and diagnostics application for hepatocellular carcinoma or, commonly known as, liver cancer. It has been shown to perform better than the conventional marker alone.

More Less

About us

Company details

Restalyst is an innovative biomedical company that develops, manufactures and markets a range of diagnostic solutions for the medical and healthcare industry.

The company’s reliable and clinically-proven diagnostic solutions include detection kits for gastric cancer, nasopharyngeal cancer and liver cancer.

The company conducts cutting-edge R&D in-house and collaborates with leading scientific partners globally to co-develop new innovations. We have been awarded and own exclusive rights to a total of 15 patents in the areas of clinical diagnostics, and continue to develop life-saving technologies.

More Less